ArticleScience translational medicine2022
Early non-neutralizing, afucosylated antibody responses are associated with COVID-19 severity.
Open access · greenAbstract read
In one paragraph
Article in Science translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 97 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
97citing papers in PubMed, 1 pooled it
13.3field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
97 citing papers in PubMed, 1 synthesis or guideline pooled it, 135 citations in OpenAlex.
- Mucosal immune response in biology, disease prevention and treatment.Signal transduction and targeted therapy · 2025Pooled it
- Article
- Mechanisms of antibody-dependent enhancement and its research progress in animal coronaviruses.Veterinary research · 2026Review
- Longitudinal Changes in IgG N-glycome Are Associated with Disease Severity and Mortality in COVID-19 Patients.Viruses · 2026Article
- High Frequencies of Senescent and Exhausted Natural Killer Cells and SARS-CoV-2-Specific Memory CD8Viruses · 2026Article
- Subclinical exposure to Streptococcus pyogenes drives the development of long-lived homologous immunity.Nature communications · 2026Article
- Vaccination-first immune priming shapes a sustained mRNA vaccine-induced IgG4 class switch that associates with SARS-CoV-2 breakthrough infection risk.Scientific reports · 2026Article
- Pharmacologic glycoengineering of Fcγ receptor IIIa enhances force-resistant IgG-FcγR interactions and anti-tumor antibody efficacy.Immunity · 2026Article
- Antibody-Dependent Immune Complex Signaling and Inflammatory Cytokine Responses in Acute Febrile Illness: A Mechanistic Study in Arboviral and Leptospiral Infection.Open forum infectious diseases · 2026Article
- Glycan Structures of Human Immunoglobulins and Their Roles.Advances in experimental medicine and biology · 2026Review
- Class switching toward IgG4 six months after primary mRNA-based COVID-19 vaccination in kidney patients.PloS one · 2026Article
- Glycosylated IgG antibodies contribute to the recovery of haemorrhagic fever with renal syndrome patients.eLife · 2025Article
- SARS-CoV-2-specific B cell responses in non-draining lymph nodes and antibody functionalities in immunized end-stage renal disease patients.Scientific reports · 2025Article
- Asymmetrically glycosylated IgG1 antibodies are universal and drive human disease.Nature communications · 2025Article
- Hyperinflammation by Human Macrophages Induced by SARS-CoV-2 Anti-Spike IgG Is Dependent on Glucose and Fatty Acid Metabolism.European journal of immunology · 2025Article
- Afucosylation of anti-dengue IgG is associated with enhanced susceptibility to dengue virus infection postvaccination.Science translational medicine · 2025Article
- Afucosylated IgG Promote Thrombosis in Mouse Injected with SARS-CoV-2 Spike Expressing Megakaryocytes.International journal of molecular sciences · 2025Article
- FcγRIIIa is a noncanonical costimulatory molecule for CD8 T cells.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Endemic coronavirus infection is associated with SARS-CoV-2 Fc receptor-binding antibodies.Journal of virology · 2025Article
- Impact of age and prior COVID-19 on the response to influenza a components in the 2020-2021 Fluzone vaccine.Vaccine · 2025Article
37 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
42 authors at 10 institutions in 1 country.
Saborni ChakrabortyDepartment of Medicine, Division of Infectious Diseases, Stanford University, Stanford, CA 94304, USA.ORCID 0000-0003-0502-3757
Joseph C GonzalezDepartment of Medicine, Division of Infectious Diseases, Stanford University, Stanford, CA 94304, USA.ORCID 0000-0002-3282-0041
Benjamin L SieversJ. Craig Venter Institute, La Jolla, CA 92037, USA.ORCID 0000-0002-9681-9082
Vamsee MallajosyulaInstitute for Immunity, Transplantation and Infection, Stanford University School of Medicine, Stanford, CA 94305, USA.ORCID 0000-0002-0658-3652
Srijoni ChakrabortyDepartment of Computer and Software Engineering, San José State University, San Jose, CA 95192, USA.
Megha DubeyDepartment of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA 94305, USA.ORCID 0000-0001-7119-6504
Usama AshrafDepartment of Medicine, Division of Infectious Diseases, Stanford University, Stanford, CA 94304, USA.ORCID 0000-0001-8686-9054
Bowie Yik-Ling ChengDepartment of Medicine, Division of Infectious Diseases, Stanford University, Stanford, CA 94304, USA.ORCID 0000-0003-0794-6133
Nimish KathaleDepartment of Medicine, Division of Infectious Diseases, Stanford University, Stanford, CA 94304, USA.
Kim Quyen Thi TranDepartment of Medicine, Division of Infectious Diseases, Stanford University, Stanford, CA 94304, USA.
Courtney ScallanDepartment of Medicine, Division of Infectious Diseases, Stanford University, Stanford, CA 94304, USA.ORCID 0000-0003-4371-8744
Aanika SinnottJ. Craig Venter Institute, La Jolla, CA 92037, USA.ORCID 0000-0002-3445-5930
Arianna CassidyDivision of Maternal-Fetal Medicine, Department of Obstetrics, Gynecology and Reproductive Sciences, University of California San Francisco, San Francisco, CA 94143, USA.
Steven T ChenPrecision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029-5674, USA.
Terri GelbartJ. Craig Venter Institute, La Jolla, CA 92037, USA.ORCID 0000-0002-7863-1262
Fei GaoInstitute for Immunity, Transplantation and Infection, Stanford University School of Medicine, Stanford, CA 94305, USA.
Yarden GolanDepartment of Bioengineering and Therapeutic Sciences and Institute for Human Genetics, University of California San Francisco, San Francisco, CA 94143, USA.ORCID 0000-0002-3043-3638
Xuhuai JiInstitute for Immunity, Transplantation and Infection, Stanford University School of Medicine, Stanford, CA 94305, USA.ORCID 0000-0002-1768-6403
Seunghee Kim-SchulzePrecision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029-5674, USA.
Mary PrahlDivision of Pediatric Infectious Diseases, Department of Pediatrics, University of California, San Francisco, CA 94143, USA.ORCID 0000-0003-0091-2731
Stephanie L GawDivision of Maternal-Fetal Medicine, Department of Obstetrics, Gynecology and Reproductive Sciences, University of California San Francisco, San Francisco, CA 94143, USA.ORCID 0000-0003-0891-6964
Sacha GnjaticPrecision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029-5674, USA.ORCID 0000-0001-5643-9520
Thomas U MarronPrecision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029-5674, USA.ORCID 0000-0001-5903-8191
Miriam MeradPrecision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029-5674, USA.ORCID 0000-0002-4481-7827
Prabhu S ArunachalamInstitute for Immunity, Transplantation and Infection, Stanford University School of Medicine, Stanford, CA 94305, USA.ORCID 0000-0003-0090-5689
Scott D BoydDepartments of Pathology and of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA 94305, USA.ORCID 0000-0003-0963-044X
Mark M DavisInstitute for Immunity, Transplantation and Infection, Stanford University School of Medicine, Stanford, CA 94305, USA.ORCID 0000-0001-6868-657X
Marisa HolubarDepartment of Medicine, Division of Infectious Diseases, Stanford University, Stanford, CA 94304, USA.ORCID 0000-0002-7585-1809
Chaitan KhoslaDepartments of Chemistry and Chemical Engineering, Stanford University, Stanford, CA 94305, USA.ORCID 0000-0001-6529-495X
Holden T MaeckerInstitute for Immunity, Transplantation and Infection, Stanford University School of Medicine, Stanford, CA 94305, USA.ORCID 0000-0003-0795-9946
Yvonne MaldonadoDepartment of Pediatrics, Stanford University School of Medicine, Stanford, CA 94305, USA.
Elizabeth D MellinsDepartment of Pediatrics, Stanford University School of Medicine, Stanford, CA 94305, USA.ORCID 0000-0003-2577-139X
Kari C NadeauSean N. Parker Center for Allergy and Asthma Research, Stanford University, Stanford, CA 94304, USA.ORCID 0000-0002-2146-2955
Bali PulendranInstitute for Immunity, Transplantation and Infection, Stanford University School of Medicine, Stanford, CA 94305, USA.ORCID 0000-0001-6517-4333
Upinder SinghDepartment of Medicine, Division of Infectious Diseases, Stanford University, Stanford, CA 94304, USA.ORCID 0000-0003-0630-0306
Aruna SubramanianDepartment of Medicine, Division of Infectious Diseases, Stanford University, Stanford, CA 94304, USA.ORCID 0000-0002-1373-6768
Paul J UtzDepartment of Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA 94304, USA.ORCID 0000-0003-1181-1565
Robert SherwoodProteomics and Metabolomics Facility, Institute of Biotechnology, Cornell University, Ithaca, NY 14853, USA.
Sheng ZhangProteomics and Metabolomics Facility, Institute of Biotechnology, Cornell University, Ithaca, NY 14853, USA.ORCID 0000-0001-8206-1007
Prasanna JagannathanDepartment of Medicine, Division of Infectious Diseases, Stanford University, Stanford, CA 94304, USA.ORCID 0000-0001-6305-758X
Gene S TanJ. Craig Venter Institute, La Jolla, CA 92037, USA.ORCID 0000-0002-8965-1509
Taia T WangDepartment of Medicine, Division of Infectious Diseases, Stanford University, Stanford, CA 94304, USA.ORCID 0000-0002-3894-685X
Stanford University · USJ. Craig Venter Institute · USTisch Hospital · USUniversity of California, San Francisco · USCornell University · USSan Jose State University · USChan Zuckerberg Initiative (United States) · USHoward Hughes Medical Institute · USIcahn School of Medicine at Mount Sinai · USQB3 · US
Funding
Using a tonsil organoid system to probe conditions for the induction of protective antibody and T cell responses to influenza.U19AI057229 · NIAID · STANFORD UNIVERSITY · PI Mark Morris Davis · 2003 to 2026
$88.5MMOLECULAR &CELLULAR IMMUNOBIOLOGYT32AI007290 · NIAID · STANFORD UNIVERSITY · PI Sean Curtis Bendall, Olivia M Martinez · 1985 to 2026
$27.0MUnderstanding B cell memory in response to diverse virus infectionsU19AI111825 · NIAID · ROCKEFELLER UNIVERSITY · PI BOURNAZOS, STYLIANOS · 2014 to 2023
$26.0MHigh-Dimensional Immune Monitoring of NCI-Supported Immunotherapy TrialsU24CA224319 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Sacha Gnjatic, Seunghee Kim-Schulze · 2017 to 2026
$21.5MThe effects of immune-age on immune-response and the molecular mechanisms which drive itP01AI153559 · NIAID · STANFORD UNIVERSITY · PI DAVIS, MARK MORRIS · 2021 to 2025
$17.8MSystems biological assessment of T cell responses to vaccinationU19AI167903 · NIAID · STANFORD UNIVERSITY · PI BALI PULENDRAN · 2022 to 2026
$13.2MProject 3: T CellsU54CA260517 · NCI · STANFORD UNIVERSITY · PI DAVIS, MARK MORRIS · 2020 to 2024
$10.4MComputational models of naturally acquired immunity to falciparum malariaU01AI150741 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BUTTE, ATUL J, GREENHOUSE, BRYAN R · 2020 to 2024
$7.4MGiant MagnetoResistive (GMR) Sensors for Measuring Influenza VaccineR01AI125197 · NIAID · STANFORD UNIVERSITY · PI UTZ, PAUL JOSEPH, WANG, SHAN X. · 2016 to 2021
$5.0MCharacterizing and predicting colitis in immune checkpoint blockade-treated cancer patientsU01DK124165 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI COLOMBEL, JEAN-FREDERIC, FAITH, JEREMIAH JAMES · 2020 to 2024
$2.9MRegulation of the IgG Fc domain repertoireR01AI139119 · NIAID · STANFORD UNIVERSITY · PI WANG, TAIA · 2019 to 2023
$2.8MMentoring translational scientists in international infectious disease researchK24AI144048 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Bryan R Greenhouse · 2019 to 2026
$1.6MNCI NIH HHS U24 CA224319NCI NIH HHS U54 CA260517NIAID NIH HHS K23 AI076614NIAID NIH HHS K24 AI144048NIAID NIH HHS P01 AI153559NIAID NIH HHS R01 AI125197NIAID NIH HHS R01 AI139119NIAID NIH HHS T32 AI007290NIAID NIH HHS U01 AI150741NIAID NIH HHS U19 AI057229NIAID NIH HHS U19 AI111825NIAID NIH HHS U19 AI167903NIDDK NIH HHS U01 DK124165
Abstract
A damaging inflammatory response is implicated in the pathogenesis of severe coronavirus disease 2019 (COVID-19), but mechanisms contributing to this response are unclear. In two prospective cohorts, early non-neutralizing, afucosylated immunoglobulin G (IgG) antibodies specific to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were associated with progression from mild to more severe COVID-19. To study the biology of afucosylated IgG immune complexes, we developed an in vivo model that revealed that human IgG-Fc-gamma receptor (FcγR) interactions could regulate inflammation in the lung. Afucosylated IgG immune complexes isolated from patients with COVID-19 induced inflammatory cytokine production and robust infiltration of the lung by immune cells. In contrast to the antibody structures that were associated with disease progression, antibodies that were elicited by messenger RNA SARS-CoV-2 vaccines were highly fucosylated and enriched in sialylation, both modifications that reduce the inflammatory potential of IgG. Vaccine-elicited IgG did not promote an inflammatory lung response. These results show that human IgG-FcγR interactions regulate inflammation in the lung and define distinct lung activities mediated by the IgG that are associated with protection against, or progression to, severe COVID-19.
Indexed as
COVID-19Antibodies, NeutralizingAntibodies, ViralAntibody FormationCOVID-19 VaccinesHumansProspective StudiesSARS-CoV-2Spike Glycoprotein, CoronavirusAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.